Abigail G. Herrmann

Tau association with synaptic vesicles causes presynaptic dysfunction

Tau is implicated in more than 20 neurodegenerative diseases, including Alzheimers disease. Under pathological conditions, Tau dissociates from axonal microtubules and missorts to pre- and postsynaptic terminals. Patients suffer from early synaptic dysfunction prior to Tau aggregate formation, but the underlying mechanism is unclear. Here we show that pathogenic Tau binds to synaptic vesicles via its N-terminal domain and interferes with presynaptic functions, including synaptic vesicle mobility and release rate, lowering neurotransmission in fly and rat neurons. Pathological Tau mutants lacking the vesicle binding domain still localize to the presynaptic compartment but do not impair synaptic function in fly neurons. Moreover, an exogenously applied membrane-permeable peptide that competes for Tau-vesicle binding suppresses Tau-induced synaptic toxicity in rat neurons. Our work uncovers a presynaptic role of Tau that may be part of the early pathology in various Tauopathies and could be exploited therapeutically.

Adaptive changes in the neuronal proteome: mitochondrial energy production, endoplasmic reticulum stress, and ribosomal dysfunction in the cellular response to metabolic stress

Impaired energy metabolism in neurons is integral to a range of neurodegenerative diseases, from Alzheimers disease to stroke. To investigate the complex molecular changes underpinning cellular adaptation to metabolic stress, we have defined the proteomic response of the SH-SY5Y human neuroblastoma cell line after exposure to a metabolic challenge of oxygen glucose deprivation (OGD) in vitro. A total of 958 proteins across multiple subcellular compartments were detected and quantified by label-free liquid chromatography mass spectrometry. The levels of 130 proteins were significantly increased (P < 0.01) after OGD and the levels of 63 proteins were significantly decreased (P < 0.01) while expression of the majority of proteins (765) was not altered. Network analysis identified novel protein–protein interactomes involved with mitochondrial energy production, protein folding, and protein degradation, indicative of coherent and integrated proteomic responses to the metabolic challenge. Approximately one third (61) of the differentially expressed proteins was associated with the endoplasmic reticulum and mitochondria. Electron microscopic analysis of these subcellular structures showed morphologic changes consistent with the identified proteomic alterations. Our investigation of the global cellular response to a metabolic challenge clearly shows the considerable adaptive capacity of the proteome to a slowly evolving metabolic challenge.

Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease

Alzheimers disease is characterized by the presence of aggregates of amyloid beta (Aβ) in senile plaques and tau in neurofibrillary tangles, as well as marked neuron and synapse loss. Of these pathological changes, synapse loss correlates most strongly with cognitive decline. Synapse loss occurs prominently around plaques due to accumulations of oligomeric Aβ. Recent evidence suggests that tau may also play a role in synapse loss but the interactions of Aβ and tau in synapse loss remain to be determined. In this study, we generated a novel transgenic mouse line, the APP/PS1/rTg21221 line, by crossing APP/PS1 mice, which develop Aβ‐plaques and synapse loss, with rTg21221 mice, which overexpress wild‐type human tau. When compared to the APP/PS1 mice without human tau, the cross‐sectional area of ThioS+ dense core plaques was increased by ~50%. Along with increased plaque size, we observed an increase in plaque‐associated dystrophic neurites containing misfolded tau, but there was no exacerbation of neurite curvature or local neuron loss around plaques. Array tomography analysis similarly revealed no worsening of synapse loss around plaques, and no change in the accumulation of Aβ at synapses. Together, these results indicate that adding human wild‐type tau exacerbates plaque pathology and neurite deformation but does not exacerbate plaque‐associated synapse loss.

Non-fibrillar oligomeric amyloid-β within synapses

Alzheimers disease (AD) is characterized by memory loss, insidious cognitive decline, profound neurodegeneration, and the extracellular accumulation of amyloid-β (Aβ) peptide in senile plaques and intracellular accumulation of tau in neurofibrillary tangles. Loss and dysfunction of synapses are believed to underlie the devastating cognitive decline in AD. A large amount of evidence suggests that oligomeric forms of Aβ associated with senile plaques are toxic to synapses, but the precise sub-synaptic localization of Aβ and which forms are synaptotoxic remain unknown. Here, we characterize the sub-synaptic localization of Aβ oligomers using three high-resolution imaging techniques, stochastic optical reconstruction microscopy, immunogold electron microscopy, and Förster resonance energy transfer in a plaque-bearing mouse model of AD. With all three techniques, we observe oligomeric Aβ inside synaptic terminals. Further, we tested a panel of Aβ antibodies using the relatively high-throughput array tomography technique to determine which forms are present in synapses. Our results show that different oligomeric Aβ species are present in synapses and highlight the potential of array tomography for rapid testing of aggregation state specific Aβ antibodies in brain tissue.

Clearing the way for tau immunotherapy in Alzheimer's disease.

Alzheimer’s disease (AD), the most common cause of dementia, is a major unmet health challenge of the 21st century. More than 35 million people suffer with dementia worldwide, a figure set to rise to over 100 million by 2050 (projections from the Prince et al. 2013). AD encompasses a host of pathophysiological hallmarks, including extensive amyloid-b deposition (in the form of extracellular plaques and cerebral amyloid angiopathy), tau inclusions (notably in intracellular neurofibrillary tangles and neuropil threads), extensive synaptic and neuronal loss, microglial activation, astrogliosis and inflammation. Of these pathological features, amyloid-b is strongly implicated as the initiating factor in the disease, but synapse loss and neurofibrillary tangle accumulation correlate most strongly with dementia (Hardy 1997; Ingelsson et al. 2004). Despite enormous research efforts to understand the biochemical links between these pathologies and AD progression, drug treatments available to patients remain severely limited. All of the recent clinical trials aimed at reducing amyloid-b levels have failed dramatically, resulting in heated debate in the field about effectiveness of amyloid-based therapeutics (Karran et al. 2011). In the current issue of Journal of Neurochemistry, Ittner et al. (2014) provide new support for a tau-based immunotherapy approach in the treatment of AD and other tauopathies. There is an emerging consensus that tau protein presents a promising therapeutic target in the treatment of AD. A steady increase in abundance of neurofibrillary tangles and their spread through the brain strongly correlates with the progressive cognitive decline associated with AD. This slowly evolving tau pathological profile is in contrast to amyloid-b progression, as amyloid plaque burden peaks during pre-clinical stages of AD and reaches a plateau by the onset of cognitive symptoms. This indicates that while amyloid-b is clearly important for disease initiation, therapies aimed at reducing amyloid levels may be ineffective at the stage when patients exhibit symptoms. Conversely, targeting tau may be more effective during the symptomatic stages of the disease. One of the important lessons learned in the development of amyloid therapeutics was that immunotherapy is effective at lowering levels of pathological proteins in the brain. Pioneering work from Schenk and colleagues showed that immunization with amyloid-b can successfully clear amyloid pathology and induce cognitive improvements in mouse models of plaque deposition. This idea was quickly expanded to show that passive immunization with amyloid-b antibodies can be similarly beneficial (Schenk et al. 2012). Immunotherapy has recently been harnessed to target tau in mouse models, with promising results. In frontotemporal dementia-associated P301L mutant tau transgenic mice, the Sigurdsson group has found that both active and passive tau immunotherapies are effective in reducing brain levels of aggregated tau and in preventing cognitive decline (Boutajangout et al. 2011). The efficacy of tau immunotherapy has been confirmed in numerous mouse models and through the targeting of different potentially toxic species, including several phosphoepitopes, misfolded tau and tau oligomers (Table 1 – reviewed by Clavaguera et al. 2014). The Ittner study in this issue utilizes two independent tau mouse models: K369I tau transgenic K3 mice, which present with an early onset and aggressive pathological tau phenotype; and P301L tau transgenic pR5 mice, which exhibit later tau pathology. Three antibodies were investigated: one antibody recognizing full-length tau (pan tau mAb – IgG1/j) and two antibodies recognizing tau phos-

Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse.

IntroductionNon-pathological, age-related cognitive decline varies markedly between individuals and places significant financial and emotional strain on people, their families and society as a whole. Understanding the differential age-related decline in brain function is critical not only for the development of therapeutics to prolong cognitive health into old age, but also to gain insight into pathological ageing such as Alzheimer’s disease. The Lothian Birth Cohort of 1936 (LBC1936) comprises a rare group of people for whom there are childhood cognitive test scores and longitudinal cognitive data during older age, detailed structural brain MRI, genome-wide genotyping, and a multitude of other biological, psycho-social, and epidemiological data. Synaptic integrity is a strong indicator of cognitive health in the human brain; however, until recently, it was prohibitively difficult to perform detailed analyses of synaptic and axonal structure in human tissue sections. We have adapted a novel method of tissue preparation at autopsy to allow the study of human synapses from the LBC1936 cohort in unprecedented morphological and molecular detail, using the high-resolution imaging techniques of array tomography and electron microscopy. This allows us to analyze the brain at sub-micron resolution to assess density, protein composition and health of synapses. Here we present data from the first donated LBC1936 brain and compare our findings to Alzheimer’s diseased tissue to highlight the differences between healthy and pathological brain ageing.ResultsOur data indicates that compared to an Alzheimer’s disease patient, the cognitively normal LBC1936 participant had a remarkable degree of preservation of synaptic structures. However, morphological and molecular markers of degeneration in areas of the brain associated with cognition (prefrontal cortex, anterior cingulate cortex, and superior temporal gyrus) were observed.ConclusionsOur novel post-mortem protocol facilitates high-resolution neuropathological analysis of the well-characterized LBC1936 cohort, extending phenotyping beyond cognition and in vivo imaging to now include neuro pathological changes, at the level of single synapses. This approach offers an unprecedented opportunity to study synaptic and axonal integrity during ageing and how it contributes to differences in age-related cognitive change.

The Calcium-Binding Protein EFhd2 Modulates Synapse Formation In Vitro and Is Linked to Human Dementia

Abstract EFhd2 is a calcium-binding adaptor protein that has been found to be associated with pathologically aggregated tau in the brain in Alzheimer disease and in a mouse model of frontotemporal dementia. EFhd2 has cell type–specific functions, including the modulation of intracellular calcium responses, actin dynamics, and microtubule transport. Here we report that EFhd2 protein and mRNA levels are reduced in human frontal cortex tissue affected by different types of dementia with and without tau pathology. We show that EFhd2 is mainly a neuronal protein in the brain and is abundant in the forebrain. Using short hairpin RNA–mediated knockdown of EFhd2 expression in cultured cortical neurons, we demonstrate that loss of EFhd2 affects the number of synapses developed in vitro whereas it does not alter neurite outgrowth per se. Our data suggest that EFhd2 is involved in the control of synapse development and maintenance through means other than affecting neurite development. The changes in expression levels observed in human dementias might, therefore, play a significant role in disease onset and progression of dementia, which is characterized by the loss of synapses.

Synaptic phosphorylated α-synuclein in dementia with Lewy bodies

Dementia with Lewy bodies is characterized by the accumulation of Lewy bodies and Lewy neurites in the CNS, both of which are composed mainly of aggregated α-synuclein phosphorylated at Ser129. Although phosphorylated α-synuclein is believed to exert toxic effects at the synapse in dementia with Lewy bodies and other α-synucleinopathies, direct evidence for the precise synaptic localization has been difficult to achieve due to the lack of adequate optical microscopic resolution to study human synapses. In the present study we applied array tomography, a microscopy technique that combines ultrathin sectioning of tissue with immunofluorescence allowing precise identification of small structures, to quantitatively investigate the synaptic phosphorylated α-synuclein pathology in dementia with Lewy bodies. We performed array tomography on human brain samples from five patients with dementia with Lewy bodies, five patients with Alzheimers disease and five healthy control subjects to analyse the presence of phosphorylated α-synuclein immunoreactivity at the synapse and their relationship with synapse size. Main analyses were performed in blocks from cingulate cortex and confirmed in blocks from the striatum of cases with dementia with Lewy bodies. A total of 1 318 700 single pre- or postsynaptic terminals were analysed. We found that phosphorylated α-synuclein is present exclusively in dementia with Lewy bodies cases, where it can be identified in the form of Lewy bodies, Lewy neurites and small aggregates (<0.16 µm3). Between 19% and 25% of phosphorylated α-synuclein deposits were found in presynaptic terminals mainly in the form of small aggregates. Synaptic terminals that co-localized with small aggregates of phosphorylated α-synuclein were significantly larger than those that did not. Finally, a gradient of phosphorylated α-synuclein aggregation in synapses (pre > pre + post > postsynaptic) was observed. These results indicate that phosphorylated α-synuclein is found at the presynaptic terminals of dementia with Lewy bodies cases mainly in the form of small phosphorylated α-synuclein aggregates that are associated with changes in synaptic morphology. Overall, our data support the notion that pathological phosphorylated α-synuclein may disrupt the structure and function of the synapse in dementia with Lewy bodies.

Proteomic data in meningiomas: post-proteomic analysis can reveal novel pathophysiological pathways

Meningiomas account for approximately 20% of adult primary intracranial tumours. WHO I meningiomas are the most common and are generally benign, but can progress, recur or transform to WHO II or WHO III grades over many years. A systematic review of multiple independent shotgun proteomic analyses of meningioma was performed to provide insight into underlying disease pathways. Shotgun proteomics has been conducted in seven meningioma related studies but there is considerable variation in aims, methodology, statistical power and the use of control tissue between these studies. Fifteen proteins which are different between WHO I and WHO II meningiomas and nine proteins which are different between WHO II and WHO III meningiomas have been described but without a view of their biological significance. Network analysis of proteins different between WHO I and WHO II meningiomas provided a coherent hypothesis for the involvement of these proteins in meningioma. Western blot analyses of meningioma tissue provided a measure of support for a core component in the network (involving VDAC2, APOA1 and HNF4α) but highlighted intrinsic difficulty of proteomic and biochemical analysis of meningiomas (as a consequence of gross alterations in tissue composition). Systematic review of shotgun proteomics and network analysis provides insight into meningioma pathophysiology despite the many barriers and difficulties that are inherent to this type of study.

Total variance should drive data handling strategies in third generation proteomic studies

Quantitative proteomics is entering its “third generation,” where intricate experimental designs aim to increase the spatial and temporal resolution of protein changes. This paper re‐analyses multiple internally consistent proteomic datasets generated from whole cell homogenates and fractionated brain tissue samples providing a unique opportunity to explore the different factors influencing experimental outcomes. The results clearly indicate that improvements in data handling are required to compensate for the increased mean CV associated with complex study design and intricate upstream tissue processing. Furthermore, applying arbitrary inclusion thresholds such as fold change in protein abundance between groups can lead to unnecessary exclusion of important and biologically relevant data.